A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to improve the chance of cure for people with higher risk Hodgkin
lymphoma. The purpose of the Phase I study is to test any good and bad effects of the study
drug called Nivolumab when combined with ABVD for the front-line treatment of HL.The purpose
of this Phase II study is to test whether including nivolumab in treatment for untreated
Hodgkin lymphoma can improve the chance of cure for patients with abnormal PET scans after 2
cycles of ABVD.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborators:
Barbara Ann Karmanos Cancer Institute Bristol-Myers Squibb British Columbia Cancer Agency City of Hope Medical Center M.D. Anderson Cancer Center